Get the Stockscreener App
4.05
8.58%
0.32
Pre-market:
4.04
-0.010
-0.25%
X 4 Pharmaceuticals Inc stock is traded at $4.05, with a volume of 1.07M.
It is up +8.58% in the last 24 hours and up +7.71% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.73
Open:
$3.85
24h Volume:
1.07M
Relative Volume:
2.22
Market Cap:
$368.22M
Revenue:
$35.11M
Net Income/Loss:
$-79.20M
P/E Ratio:
-0.9339
EPS:
-4.3367
Net Cash Flow:
$-88.62M
1W Performance:
-6.90%
1M Performance:
+7.71%
6M Performance:
+21.99%
1Y Performance:
-36.38%
1-Day Range:
$3.79
$4.13
1-Week Range:
$3.70
$4.435
52-Week Range:
$1.35
$6.96
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.05 | 368.22M | 35.11M | -79.20M | -88.62M | -4.3367 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 112.92B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 81.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 48.82B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 43.66B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 34.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Guggenheim | Buy |
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Weekly Trades: Is X4 Pharmaceuticals Inc stock a value trapQuarterly Trade Review & Reliable Price Breakout Alerts - baoquankhu1.vn
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists - PR Newswire
Meme Stocks: Is X4 Pharmaceuticals Inc a momentum stock2026 Intraday Action & Stepwise Swing Trade Plans - baoquankhu1.vn
Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeutics, Disease Prevalence, Mechanisms, Market Size, Key Companies | DelveInsight - Barchart
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for - GlobeNewswire
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors - TMX Newsfile
Aug Selloffs: How correlated is X4 Pharmaceuticals Inc to the S P5002026 Stock Rankings & Fast Entry Momentum Alerts - baoquankhu1.vn
Neurocrine bets nearly $3bn on deal for insatiable hunger treatment - Financial Times
Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace
XFOR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
XFOR SEC FilingsX4 Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Stonepine Capital (QNRX) files Form 4 as 10% owner with no trades - Stock Titan
Is ANIP Undervalued? How to Read Its 9.3x Forward P/E - TradingView
Tech Rally: What analysts say about X4 Pharmaceuticals Inc stock2026 Buyback Activity & Safe Capital Investment Plans - baoquankhu1.vn
Is X4 Pharmaceuticals Inc impacted by rising ratesWeekly Earnings Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Performance Recap: How does X4 Pharmaceuticals Inc score in quality rankings2026 PreEarnings & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Venrock funds trim KalVista (KALV) stake, retain 5.09M shares - Stock Titan
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Global X Japan Co. Ltd. - MarketBeat
Earnings Risk: How correlated is X4 Pharmaceuticals Inc to the S P5002026 Investor Takeaways & Fast Gain Swing Alerts - baoquankhu1.vn
XFOR|X4 Pharmaceuticals Inc|Price:4.090|Chg%:0.27 - TradingKey
[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) - Business Wire
Tarsus Pharmaceuticals (TARS) COO sells 2,989 shares in planned trade - Stock Titan
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong - WHEC.com
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review - Business Wire
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
If You Invested $1,000 in X4 Pharmaceuticals Inc (XFOR) - Stock Titan
X4 Pharmaceuticals, Inc.: Fundamental Analysis and Financial Ratings | | US98420X2027 - marketscreener.com
X4 Pharmaceuticals (NASDAQ:XFOR) Raised to Hold at Wall Street Zen - MarketBeat
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide) - PR Newswire
X4 Pharmaceuticals (NASDAQ: XFOR) seeks approval for equity plan and pay at 2026 meeting - Stock Titan
Q3 Earnings Forecast for XFOR Issued By Brookline Cap M - MarketBeat
Tarsus (NASDAQ: TARS) HR chief sells 12,274 shares in tax-related trades - Stock Titan
Tax-driven stock sale by Tarsus (TARS) chief commercial officer - Stock Titan
Children’s ibuprofen sold nationwide recalled by FDA - FOX8 WGHP
Analysts’ Top Healthcare Picks: X4 Pharmaceuticals (XFOR), Boston Scientific (BSX) - The Globe and Mail
Research Analysts Set Expectations for XFOR Q1 Earnings - MarketBeat
Crinetics Pharmaceuticals (CRNX) COO sells 9,911 shares for RSU taxes - Stock Titan
Crinetics (NASDAQ: CRNX) CSO sells shares to cover RSU tax - Stock Titan
RA Capital entities boost Acumen (NASDAQ: ABOS) stake with 6.1M-share grant - Stock Titan
X4 Pharmaceuticals (NASDAQ:XFOR) Issues Quarterly Earnings Results - MarketBeat
Amphastar (AMPH) EVP Yakob has 1,033 shares withheld for RSU tax - Stock Titan
[Form 4] Amphastar Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
X4 Pharmaceuticals, Inc. 2025 Annual Report: Business Overview, Regulatory Compliance, and Risk Factors - Minichart
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
XFOR: 4WARD Phase 3 trial progresses, EMA backs mavorixafor, and cash runway extends to 2028 - TradingView
X4 Pharmaceuticals: Q4 Earnings Snapshot - 10tv.com
EMA panel backs first WHIM syndrome drug as X4 secures cash to 2028 - Stock Titan
X4 Pharmaceuticals 2025 10-K: $35.1M Revenue, $(79.2)M Net Loss - TradingView
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
May 16 '25 |
Buy |
2.48 |
1,032 |
2,561 |
25,337 |
1.51%
1.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):